Integrated Wealth Concepts’s Galectin Therapeutics GALT Stock Holding History

Integrated Wealth Concepts’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.4K	Hold	10,000	–	–	﹤0.01%	3427
2026 Q1	$27.9K	Buy	+10,000	New	+$30.4K	﹤0.01%	2247
2025 Q4	–	Sell	-10,000	Closed	-$42.4K	–	1790
2025 Q3	$42.4K	Sell	10,000 -52	-0.5%	-$196	﹤0.01%	1952
2025 Q2	$21.2K	Buy	10,052 +42	+0.4%	+$63	﹤0.01%	1886
2025 Q1	$12.2K	Buy	10,010 +8	+0.1%	+$11	﹤0.01%	1728
2024 Q4	$12.9K	Buy	10,002 +2	+0%	+$5	﹤0.01%	1709
2024 Q3	$27.5K	Hold	10,000	–	–	﹤0.01%	1657
2024 Q2	$22.6K	Hold	10,000	–	–	﹤0.01%	1628
2024 Q1	$23.9K	Hold	10,000	–	–	﹤0.01%	1635
2023 Q4	$16.6K	Hold	10,000	–	–	﹤0.01%	1583
2023 Q3	$19.2K	Hold	10,000	–	–	﹤0.01%	1540
2023 Q2	$14.4K	Hold	10,000	–	–	﹤0.01%	1542
2023 Q1	$21K	Buy	+10,000	New	+$16.1K	﹤0.01%	1327

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Integrated Wealth Concepts's GALT Position: Q2 2026 in Review

Integrated Wealth Concepts held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 10,000 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3427.

Integrated Wealth Concepts first reported a position in GALT in Q1 2023 and has held it in 13 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Integrated Wealth Concepts held 10,000 shares of Galectin Therapeutics worth $46.4K as of Q2 2026.
Integrated Wealth Concepts left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #3427 holding.
Integrated Wealth Concepts first reported a position in Galectin Therapeutics in Q1 2023 and has held it in 13 quarters since.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.